跳转至内容
Merck
CN

SML3800

Selumetinib

≥98% (HPLC)

别名:

5-((4-Bromo-2-chlorophenyl)amino)-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-benzo[d]imidazole-6-carboxamide, 6-(4-Bromo-2-chloro-phenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxy-ethoxy)-amide, ARRY 142886, ARRY-142886, ARRY142886, AZD 6244, AZD-6244, AZD6244

登录 查看组织和合同定价。

选择尺寸

关于此项目

经验公式（希尔记法）:
C17H15BrClFN4O3
化学文摘社编号:
606143-52-6
分子量:
457.68
UNSPSC Code:
12352200
NACRES:
NA.21
MDL number:
MFCD11977472

主要文件

查看所有文档
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

SMILES string

Fc1c2nc[n](c2cc(c1Nc3c(cc(cc3)Br)Cl)C(=O)NOCCO)C

InChI

1S/C17H15BrClFN4O3/c1-24-8-21-16-13(24)7-10(17(26)23-27-5-4-25)15(14(16)20)22-12-3-2-9(18)6-11(12)19/h2-3,6-8,22,25H,4-5H2,1H3,(H,23,26)

InChI key

CYOHGALHFOKKQC-UHFFFAOYSA-N

assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 2 mg/mL, clear (Warmed)

storage temp.

2-8°C

Quality Level

100

相关类别

Biochem/physiol Actions

Orally active, potent and selective MEK1/2 inhibitor with anti-cancer efficacy in cultures and in vivo.
Selumetinib (ARRY-142886; AZD6244) is an orally active, potent and selective MEK1/2 inhibitor (MEK1 IC50 = 14 nM; <20% inhibition of >40 other kinases at 10 µM) that effectively downregulates cellular ERK1/2 phosphorylation levels (IC50 <40 nM post 1h incubation using 5 different cell lines). Selumetinib inhibits MEK1/2-dependent proliferations in cancer cultures (IC50 in nM = 59/Malme-3M, 93/SK-MEL-28, 175/HT-29, 200/SK-MEL-2, 473/MIA PaCa-2) and exhibits anti-tumor efficacy in mice in vivo (10-100 mg/kg p.o. b.i.d.; BxPC3 & HT-29 xenograft models).

pictograms

Health hazardExclamation mark
GHS08,GHS07

signalword

Warning

Hazard Classifications

Acute Tox. 4 Oral - Aquatic Chronic 4 - Repr. 2 - Skin Sens. 1 - STOT RE 2

target_organs

Gastrointestinal tract,Eyes,Urinary tract

存储类别

11 - Combustible Solids

wgk

WGK 2

flash_point_f

Not applicable

flash_point_c

Not applicable

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number
0000514884
0000514884
0000466358
0000466357
0000466357

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Barry R Davies et al.
Molecular cancer therapeutics, 6(8), 2209-2219 (2007-08-19)
Constitutive activation of the extracellular signal-regulated kinase 1/2 (ERK1/2) mitogen-activated protein kinase (MAPK) signaling pathway in human cancers is often associated with mutational activation of BRAF or RAS. MAPK/ERK kinase 1/2 kinases lie downstream of RAS and BRAF and are
Tammie C Yeh et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 13(5), 1576-1583 (2007-03-03)
The Ras-Raf-mitogen-activated protein kinase kinase (MEK) pathway is overactive in many human cancers and is thus a target for novel therapeutics. We have developed a highly potent and selective inhibitor of MEK1/2. The purpose of these studies has been to
Nikolas K Haass et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 14(1), 230-239 (2008-01-04)
Disseminated melanoma is highly therapy resistant. The finding that 66% of melanomas harbor the activating BRAF(V600E) mutation has raised expectations for targeting the Ras/RAF/mitogen-activated protein (MAP)/extracellular signal-regulated kinase (ERK) kinase (MEK)/ERK pathway in melanoma. This study addresses the anti-melanoma activity

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持